4 mg ( n = 152) or placebo ( n = 152), 92
Sue Hughes November 11, 2023 Final results of the SELECT trial have shown that the anti-obesity drug semaglutide (Wegovy) produced a consistent reduction of around 20% vs
Following successful clinical trials٫ the U
The randomised, double-blind, placebo-controlled, phase 3 SELECT trial (NCT03574597) assessed the safety and efficacy of the GLP-1 receptor agonist
4 mg reduces the risk of major adverse cardiovascular events by 20% in adults with overweight or obesity in the SELECT trial Bagsværd, Denmark, 8
Newsome et al
Management of incident DM during the trial was deferred to the treating provider, although open-label use of a GLP-1 RA was prohibited
The Select Study: Expanding Our Understanding of Obesity Management
report results from the SELECT trial, which The SUSTAIN 3 findings, published in Diabetes Care , show that semaglutide 1
However, the researchers cautioned that this could have been influenced by the "more complex device" used to administer exenatide
4 mg versus placebo as an adjunct to standard of care for The placebo groups also facilitated comparisons of semaglutide and liraglutide vs placebo (secondary trial objectives), allowing evaluation of trial results in the context of previous findings
7-mg maintenance dose was Results from the “SELECT – Semaglutide and Cardiovascular Outcomes in Patients with Overweight or Obesity Who Do Not Have Diabetes” trial were presented today during a late-breaking science session at the American Heart Association’s Scientific Sessions 2023 and simultaneously published in the New England Journal of Medicine
Rybelsus‚ also known by its generic name semaglutide‚ is an innovative oral medication used for the management of type 2 diabetes
Blaha notes that the SELECT trial examines a narrow set of severe cardiovascular events and probably underestimates semaglutide’s benefits for cardiovascular health and its potential to enhance Abstract
4 mg as compared with placebo in patients with heart failure with preserved ejection fraction, obesity, and type 2 RESULTS
Results
8 mg/week) in adults with obesity and without type 2 diabetes, which demonstrated significant, broadly dose-dependent reductions of CRP with semaglutide compared with placebo
80 and a 95% confidence interval (CI) ranging from